Phenotypes associated with this allele

• Allele Symbol: Tril^tm1.1Kaf
• Allele Name: targeted mutation 1.1, Katherine A Fitzgerald
• Allele ID: MGI:6508377
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Tril^tm1.1Kaf/Tril^tm1.1Kaf	involves: C57BL/6	MGI:6511746

Genotype
MGI:6511746

hm1

• Allelic Composition: Tril^tm1.1Kaf/Tril^tm1.1Kaf
• Genetic Background: involves: C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

abnormal cytokine secretion ( J:301765 )

• primary mixed glial cells (consisting of >83% astrocytes and ~2-3% of microglia) show a significant reduction in mRNA levels of Il6, Ccl5, Tnfa, Il1a, Il1b and Ifnb1 in response to LPS or Poly(I:C) treatment; expression levels of chemokines e.g. Cxcl2 and Ccl4 are also significantly decreased upon ligand activation

• after i.p. infection with E. coli BL21 strain, mice exhibit reduced expression levels of proinflammatory cytokines Il6, Tnfa, Il1a and Il1b as well as chemokines Ccl4, Cxcl2, Cxcl10 in the brain relative to wild-type controls

• however, bone marrow-derived macrophages (BMDMs) and bone marrow-derived dendritic cells (BMDCs) produce normal cytokine levels in response to LPS or Poly(I:C)

abnormal chemokine secretion ( J:301765 )

• in response to 24 h treatment with LPS or Poly(I:C), primary mixed glial cells show a significant decrease in CCL5 production relative to wild-type cells; after 24 h with LPS or Poly(I:C), a reduction in CCL5 production is also noted in purified astrocytes but not in immortalized migroglia cells devoid of astrocytes

• after i.p. infection with E. coli, mice exhibit significantly reduced mRNA levels of Ccl5 in the brain but not in spleen relative to wild-type controls

• after direct intracranial injection of LPS, mice show a significant decrease in Ccl5 expression in the brain relative to wild-type controls

• no differences are observed in primary mixed glial cells after treatment with the TLR2 agonist Pam3CSK4 or TLR7/8 ligand R848

decreased interferon-beta secretion ( J:301765 )

• in response to Poly(I:C) treatment, primary mixed glial cells show a significant decrease in IFNbeta protein levels relative to wild-type cells

• no differences are observed in primary mixed glial cells after treatment with the TLR2 agonist Pam3CSK4 or TLR7/8 ligand R848

decreased interleukin-6 secretion ( J:301765 )

• in response to 24 h treatment with LPS (a TLR4 ligand) or Poly(I:C) (a TLR3 ligand), primary mixed glial cells show a significant decrease in IL6 production relative to wild-type cells; after 24 h with LPS, a strong reduction of IL6 production is also noted in purified astrocytes but not in immortalized migroglia cells devoid of astrocytes

• after i.p. infection with E. coli, mice exhibit significantly reduced mRNA levels of Il6 in the brain but not in spleen relative to wild-type controls

• after direct intracranial injection of LPS, mice show a significant decrease in Il6 expression in the brain relative to wild-type controls

• no differences are observed in primary mixed glial cells after treatment with the TLR2 agonist Pam3CSK4 or TLR7/8 ligand R848

decreased tumor necrosis factor secretion ( J:301765 )

• in response to LPS treatment, primary mixed glial cells show a significant decrease in TNFalpha protein levels relative to wild-type cells

• no differences are observed in primary mixed glial cells after treatment with the TLR2 agonist Pam3CSK4 or TLR7/8 ligand R848

behavior/neurological

behavior/neurological phenotype ( J:301765 )

N • mice appear healthy and exhibit no significant alterations in anxiety, depression, general behavior, motor coordination and pain sensation relative to wild-type controls